Physician profile
Catherine Patrick
NPI 1003278565
$10,159.54
in general payments reported to CMS, 2019-2025
48 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $844 · 2021: $1,181 · 2022: $1,796 · 2023: $2,102 · 2024: $2,005 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,721.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,872.26 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $983.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Novo Nordisk INC | $919.13 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $872.36 | 2020-2025 | |
| Pfizer INC. | $582.40 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $561.43 | 2021-2025 | |
| Daiichi Sankyo INC. | $547.74 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $348.26 | 2022-2025 | Spravato, Xarelto |
| Amgen INC. | $287.90 | 2019-2025 | Repatha, Otezla, Repatha |
| Boston Scientific Corporation | $260.66 | 2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $234.33 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $219.71 | 2019-2021 | |
| Axsome Therapeutics, INC. | $185.80 | 2023-2025 | Sunosi, Auvelity |
| Phathom Pharmaceuticals, INC. | $172.70 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $164.91 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.